Arrowpoint Investment Partners’s Amgen AMGN Stock Holding History

Arrowpoint Investment Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,400	Closed	-$1.93M	–	922
2024 Q4	$1.93M	Buy	+7,400	New	+$2.2M	0.4%	53

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Arrowpoint Investment Partners's AMGN Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Amgen (AMGN) in Q2 2026, closing a stake of 4,934 shares — an estimated $1.74M sold.

Arrowpoint Investment Partners first reported a position in AMGN in Q4 2024 and held it in 4 quarters. The position peaked at $1.95M in Q4 2025. 3,156 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Arrowpoint Investment Partners reported no remaining Amgen position as of Q2 2026 after selling out during the quarter.
Arrowpoint Investment Partners sold 4,934 Amgen shares in Q2 2026, an estimated $1.74M.
Arrowpoint Investment Partners first reported a position in Amgen in Q4 2024 and held it in 4 quarters.
Arrowpoint Investment Partners's Amgen position peaked at $1.95M in Q4 2025.
3,156 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.